{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T17:35:14Z","timestamp":1790012114791,"version":"4.0.1"},"reference-count":38,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T00:00:00Z","timestamp":1773100800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100016302","name":"Coalition for Epidemic Preparedness Innovations","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016302","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005624","name":"PATH","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005624","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journalofinfection.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Infection"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.jinf.2026.106727","type":"journal-article","created":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T08:46:27Z","timestamp":1773391587000},"page":"106727","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Immunogenicity and efficacy over 12 months following a fourth dose of a bivalent mRNA or protein-based COVID-19 vaccine: A randomised controlled trial in Australia"],"prefix":"10.1016","volume":"92","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7681-2775","authenticated-orcid":false,"given":"Nadia","family":"Mazarakis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0282-5837","authenticated-orcid":false,"given":"Zheng Quan","family":"Toh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7998-0942","authenticated-orcid":false,"given":"Eleanor","family":"Neal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0599-8645","authenticated-orcid":false,"given":"Cattram","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn","family":"Bright","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Skyy","family":"Luu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leanne","family":"Quah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5999-5661","authenticated-orcid":false,"given":"Yan Yung","family":"Ng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Hart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lien Anh Ha","family":"Do","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Rudel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shashini","family":"Dassanayake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2750-7261","authenticated-orcid":false,"given":"Rachel A.","family":"Higgins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachael","family":"Carissa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6409-1376","authenticated-orcid":false,"given":"Darren Suryawijaya","family":"Ong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frances","family":"Justice","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerryn A.","family":"Moore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6309-6842","authenticated-orcid":false,"given":"Emma","family":"Watts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kanta","family":"Subbarao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim","family":"Mulholland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"von Mollendorf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6086-6285","authenticated-orcid":false,"given":"Paul V.","family":"Licciardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jinf.2026.106727_bib1","unstructured":"The World Health Organization. WHO COVID-19 dashboard. \u3008https:\/\/data.who.int\/dashboards\/covid19\/deaths2025\u3009 [updated 9th February 2025]."},{"issue":"1","key":"10.1016\/j.jinf.2026.106727_bib2","doi-asserted-by":"crossref","first-page":"e6","DOI":"10.1016\/S1473-3099(24)00738-2","article-title":"Enhanced immune evasion of SARS-CoV-2 variants KP.3.1.1 and XEC through N-terminal domain mutations","volume":"25","author":"Liu","year":"2025","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.jinf.2026.106727_bib3","article-title":"Effectiveness of COVID-19 vaccination against COVID-19 specific and all-cause mortality in older Australians: a population based study","volume":"40","author":"Liu","year":"2023","journal-title":"Lancet Reg Health West Pac"},{"issue":"5","key":"10.1016\/j.jinf.2026.106727_bib4","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/S2213-2600(23)00015-2","article-title":"Long-term effectiveness of COVID-19 vaccines against infections, hospitalisations, and mortality in adults: findings from a rapid living systematic evidence synthesis and meta-analysis up to December, 2022","volume":"11","author":"Wu","year":"2023","journal-title":"Lancet Respir Med"},{"issue":"4","key":"10.1016\/j.jinf.2026.106727_bib5","doi-asserted-by":"crossref","first-page":"77","DOI":"10.15585\/mmwr.mm7304a2","volume":"73","author":"Link-Gelles","year":"2024","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.jinf.2026.106727_bib6","unstructured":"Organization\u00a0WH. COVID-19 advice for the public: getting vaccinated;\u00a02024.\u00a0\u3008https:\/\/www.who.int\/emergencies\/diseases\/novel-coronavirus-2019\/covid-19-vaccines\/advice\u3009."},{"issue":"11","key":"10.1016\/j.jinf.2026.106727_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.lanhl.2024.100646","article-title":"Global landscape of COVID-19 vaccination programmes for older adults: a descriptive study","volume":"5","author":"Zheng","year":"2024","journal-title":"Lancet Healthy Longev"},{"issue":"42","key":"10.1016\/j.jinf.2026.106727_bib8","doi-asserted-by":"crossref","first-page":"6221","DOI":"10.1016\/j.vaccine.2023.08.080","article-title":"Understanding low COVID-19 booster uptake among US adults","volume":"41","author":"Jacobs","year":"2023","journal-title":"Vaccine"},{"key":"10.1016\/j.jinf.2026.106727_bib9","first-page":"141","article-title":"Should you pick Novavax\u2019s COVID-19 shot over mRNA options?","volume":"382","author":"Couzin-Frankel","year":"2023","journal-title":"ScienceInsider"},{"issue":"3","key":"10.1016\/j.jinf.2026.106727_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.jinf.2025.106447","article-title":"The immunogenicity, reactogenicity, and safety of a bivalent mRNA or protein COVID-19 vaccine given as a fourth dose","volume":"90","author":"Mazarakis","year":"2025","journal-title":"J Infect"},{"key":"10.1016\/j.jinf.2026.106727_bib11","unstructured":"(ATAGI) ATAGoI. ATAGI update on the COVID-19 vaccination program;\u00a02023.\u00a0\u3008https:\/\/www.health.gov.au\/news\/atagi-update-on-the-covid-19-vaccination-program\u3009."},{"issue":"3","key":"10.1016\/j.jinf.2026.106727_bib12","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.1313","article-title":"Comparison of seroconversion in children and adults with mild COVID-19","volume":"5","author":"Toh","year":"2022","journal-title":"JAMA Netw Open"},{"issue":"1","key":"10.1016\/j.jinf.2026.106727_bib13","doi-asserted-by":"crossref","first-page":"7185","DOI":"10.1038\/s41467-022-34983-2","article-title":"Comparison of antibody responses to SARS-CoV-2 variants in Australian children","volume":"13","author":"Toh","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.jinf.2026.106727_bib14","article-title":"The estimands framework: a primer on the ICH E9(R1) addendum","volume":"384","author":"Kahan","year":"2024","journal-title":"BMJ"},{"key":"10.1016\/j.jinf.2026.106727_bib15","unstructured":"Agency EM. ICH E9 (R1) addendum on estimands and sensitivity analysis in clinical trials to the guideline on statistical principles for clinical trials;\u00a02020. \u3008https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/ich-e9-r1-addendum-estimands-sensitivity-analysis-clinical-trials-guideline-statistical-principles_en.pdf\u3009."},{"key":"10.1016\/j.jinf.2026.106727_bib16","series-title":"Multiple imputation for nonresponse in surveys","author":"Rubin","year":"1987"},{"issue":"1","key":"10.1016\/j.jinf.2026.106727_bib17","doi-asserted-by":"crossref","first-page":"8569","DOI":"10.1038\/s41467-025-63598-6","article-title":"Immunogenicity of fractional and standard dose COVID-19 vaccine boosters among healthy adults in Indonesia: twenty four month follow-up from a randomised controlled trial","volume":"16","author":"Hart","year":"2025","journal-title":"Nat Commun"},{"key":"10.1016\/j.jinf.2026.106727_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.vaccine.2025.127840","article-title":"Immunogenicity and safety at twelve months of fractional and standard BNT162b2 booster doses in adults primed with ChAdOx1-S, BBIBP-CorV, or Gam-COVID-Vac in Mongolia: a randomised controlled trial","volume":"66","author":"Batmunkh","year":"2025","journal-title":"Vaccine"},{"issue":"23","key":"10.1016\/j.jinf.2026.106727_bib19","doi-asserted-by":"crossref","first-page":"4121","DOI":"10.1093\/bioinformatics\/bty407","article-title":"Nextstrain: real-time tracking of pathogen evolution","volume":"34","author":"Hadfield","year":"2018","journal-title":"Bioinformatics"},{"key":"10.1016\/j.jinf.2026.106727_bib20","unstructured":"GISAID. hCoV-19 (SARS-CoV-2) variants and lineages;\u00a02025\u00a0\u3008https:\/\/gisaid.org\/hcov-19-variants-dashboard\/\u3009."},{"key":"10.1016\/j.jinf.2026.106727_bib21","article-title":"Effectiveness of the fourth dose of COVID-19 vaccines against severe COVID-19 among adults 40 years or older in Brazil: a population-based cohort study","volume":"34","author":"Lazar Neto","year":"2024","journal-title":"Lancet Reg Health Am"},{"issue":"8","key":"10.1016\/j.jinf.2026.106727_bib22","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1016\/S1473-3099(22)00271-7","volume":"22","author":"Munro","year":"2022","journal-title":"Lancet Infect Dis"},{"issue":"1","key":"10.1016\/j.jinf.2026.106727_bib23","doi-asserted-by":"crossref","first-page":"7711","DOI":"10.1038\/s41467-022-35480-2","article-title":"Immunogenicity and efficacy of fourth BNT162b2 and mRNA1273 COVID-19 vaccine doses; three months follow-up","volume":"13","author":"Canetti","year":"2022","journal-title":"Nat Commun"},{"issue":"1","key":"10.1016\/j.jinf.2026.106727_bib24","doi-asserted-by":"crossref","first-page":"4575","DOI":"10.1038\/s41467-023-39816-4","article-title":"Correlates of protection for booster doses of the SARS-CoV-2 vaccine BNT162b2","volume":"14","author":"Hertz","year":"2023","journal-title":"Nat Commun"},{"issue":"29","key":"10.1016\/j.jinf.2026.106727_bib25","doi-asserted-by":"crossref","first-page":"4280","DOI":"10.1016\/j.vaccine.2023.05.051","article-title":"Immunogenicity and safety of a fourth homologous dose of NVX-CoV2373","volume":"41","author":"Alves","year":"2023","journal-title":"Vaccine"},{"issue":"6","key":"10.1016\/j.jinf.2026.106727_bib26","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/s41577-022-00716-1","article-title":"Disentangling the relative importance of T cell responses in COVID-19: leading actors or supporting cast?","volume":"22","author":"Kent","year":"2022","journal-title":"Nat Rev Immunol"},{"issue":"1","key":"10.1016\/j.jinf.2026.106727_bib27","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s12979-023-00406-z","article-title":"Accelarated immune ageing is associated with COVID-19 disease severity","volume":"21","author":"Lord","year":"2024","journal-title":"Immun Ageing"},{"issue":"4","key":"10.1016\/j.jinf.2026.106727_bib28","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1038\/s41577-022-00785-2","article-title":"COVID-19 and cellular senescence","volume":"23","author":"Schmitt","year":"2023","journal-title":"Nat Rev Immunol"},{"issue":"24","key":"10.1016\/j.jinf.2026.106727_bib29","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1056\/NEJMsb2506929","article-title":"An evidence-based approach to covid-19 vaccination","volume":"392","author":"Prasad","year":"2025","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.jinf.2026.106727_bib30","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1016\/S1473-3099(22)00420-0","article-title":"Safety and immunogenicity following a homologous booster dose of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373): a secondary analysis of a randomised, placebo-controlled, phase 2 trial","volume":"22","author":"Mallory","year":"2022","journal-title":"Lancet Infect Dis"},{"issue":"5","key":"10.1016\/j.jinf.2026.106727_bib31","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1038\/s41591-022-01739-w","article-title":"Immune response to SARS-CoV-2 after a booster of mRNA-1273: an open-label phase 2 trial","volume":"28","author":"Chu","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.jinf.2026.106727_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.vaccine.2025.126869","article-title":"A phase 2\/3 trial to investigate the safety and immunogenicity of monovalent Omicron JN.1-adapted BNT162b2 COVID-19 vaccine in adults >\/=18 years old","volume":"52","author":"Diya","year":"2025","journal-title":"Vaccine"},{"issue":"12","key":"10.1016\/j.jinf.2026.106727_bib33","doi-asserted-by":"crossref","first-page":"e732","DOI":"10.1016\/S1473-3099(24)00688-1","article-title":"Impact of JN.1 booster vaccination on neutralisation of SARS-CoV-2 variants KP.3.1.1 and XEC","volume":"24","author":"Arora","year":"2024","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.jinf.2026.106727_bib34","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofaf705","article-title":"Immunogenicity of JN.1- and KP.2-Encoding mRNA COVID-19 Vaccines Against JN.1 Subvariants in Adult Participants","volume":"12","author":"Figueroa","year":"2025","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.jinf.2026.106727_bib35","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/S1473-3099(25)00380-9","article-title":"Effectiveness of the BNT162b2 and mRNA-1273 JN.1-adapted vaccines against COVID-19-associated hospitalisation and death: a Danish, nationwide, register-based, cohort study","volume":"25","author":"Hansen","year":"2025","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.jinf.2026.106727_bib36","doi-asserted-by":"crossref","DOI":"10.1016\/j.vaccine.2025.128164","article-title":"Safety and immunogenicity of a single dose of a JN.1 variant COVID-19 vaccine in previously vaccinated adults: Primary analysis report of a phase 3 open-label trial","volume":"73","author":"Alves","year":"2026","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.jinf.2026.106727_bib37","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1038\/s41392-025-02154-6","article-title":"A recombinant protein vaccine induces protective immunity against SARS-CoV-2 JN.1 and XBB-lineage subvariants","volume":"10","author":"Yang","year":"2025","journal-title":"Signal Transduct Target Ther"},{"issue":"88","key":"10.1016\/j.jinf.2026.106727_bib38","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.adg7015","article-title":"Efficacy of mRNA-1273 and Novavax ancestral or BA.1 spike booster vaccines against SARS-CoV-2 BA.5 infection in nonhuman primates","volume":"8","author":"Routhu","year":"2023","journal-title":"Sci Immunol"}],"updated-by":[{"DOI":"10.1016\/j.jinf.2026.106851","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000}}],"container-title":["Journal of Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163445326000526?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163445326000526?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,13]],"date-time":"2026-09-13T19:41:49Z","timestamp":1789328509000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0163445326000526"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":38,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S0163445326000526"],"URL":"https:\/\/doi.org\/10.1016\/j.jinf.2026.106727","relation":{},"ISSN":["0163-4453"],"issn-type":[{"value":"0163-4453","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunogenicity and efficacy over 12 months following a fourth dose of a bivalent mRNA or protein-based COVID-19 vaccine: A randomised controlled trial in Australia","name":"articletitle","label":"Article Title"},{"value":"Journal of Infection","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jinf.2026.106727","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd on behalf of British Infection Association.","name":"copyright","label":"Copyright"}],"article-number":"106727"}}